Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.19 USD | -3.35% | -1.04% | +49.03% |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+49.03% | 1.88B | B- | ||
+9.58% | 115B | B+ | ||
+12.41% | 107B | B+ | ||
-3.46% | 21.6B | B | ||
-12.38% | 22.31B | B+ | ||
-6.87% | 19.19B | A- | ||
-3.35% | 18.23B | B | ||
-38.57% | 17.62B | A- | ||
+7.51% | 14.26B | C+ | ||
+35.67% | 12.37B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AGIO Stock
- Ratings Agios Pharmaceuticals, Inc.